Literature DB >> 9496296

Hypnosis in chronic fatigue syndrome.

V H Gregg1.   

Abstract

Entities:  

Mesh：

Year:  1997        PMID： 9496296      PMCID： PMC1296740          DOI： 10.1177/014107689709001213

Source DB:  PubMed          Journal:  J R Soc Med        ISSN： 0141-0768            Impact factor:   5.344


× No keyword cloud information.
  7 in total

1.  Hypnosis as an adjunct to cognitive-behavioral psychotherapy: a meta-analysis.

Authors:  I Kirsch; G Montgomery; G Sapirstein
Journal:  J Consult Clin Psychol       Date:  1995-04

2.  Cognitive behavior therapy for chronic fatigue syndrome: a randomized controlled trial.

Authors:  A Deale; T Chalder; I Marks; S Wessely
Journal:  Am J Psychiatry       Date:  1997-03       Impact factor: 18.112

3.  Epidemiology, antimicrobial susceptibility, pathogenicity, and significance of Bacteroides fragilis group organisms isolated at Los Angeles County-University of Southern California Medical Center.

Authors:  M D Appleman; P N Heseltine; C E Cherubin
Journal:  Rev Infect Dis       Date:  1991 Jan-Feb

4.  Chronic fatigue syndrome: a cognitive approach.

Authors:  C Surawy; A Hackmann; K Hawton; M Sharpe
Journal:  Behav Res Ther       Date:  1995-06

5.  A comparative psychiatric assessment of patients with chronic fatigue syndrome and muscle disease.

Authors:  G C Wood; R P Bentall; M Göpfert; R H Edwards
Journal:  Psychol Med       Date:  1991-08       Impact factor: 7.723

6.  Cognitive behaviour therapy for the chronic fatigue syndrome: a randomized controlled trial.

Authors:  M Sharpe; K Hawton; S Simkin; C Surawy; A Hackmann; I Klimes; T Peto; D Warrell; V Seagroatt
Journal:  BMJ       Date:  1996-01-06

7.  A report--chronic fatigue syndrome: guidelines for research.

Authors:  M C Sharpe; L C Archard; J E Banatvala; L K Borysiewicz; A W Clare; A David; R H Edwards; K E Hawton; H P Lambert; R J Lane
Journal:  J R Soc Med       Date:  1991-02       Impact factor: 18.000
  7 in total
  1 in total

1.  Raltegravir is a potent inhibitor of XMRV, a virus implicated in prostate cancer and chronic fatigue syndrome.

Authors:  Ila R Singh; John E Gorzynski; Daria Drobysheva; Leda Bassit; Raymond F Schinazi
Journal:  PLoS One       Date:  2010-04-01       Impact factor: 3.240
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.